公开(公告)号：US20240424210A1

公开(公告)日：2024-12-26

申请号：US18749512

申请日：2024-06-20

Applicant: INSULET CORPORATION

Inventor： Mert SEVIL ,  Yibin ZHENG ,  William WHITELEY ,  Rangarajan NARAYANASWAMI ,  Saeed SALAVATI ,  Sam CARL

IPC: A61M5/172 ,  G16H20/17

Abstract: Disclosed are a drug delivery system, a drug delivery device, a controller and a number of techniques to personalize the delivery of a bolus dosage. In an example, a drug delivery system may include a processor and a memory. The memory may be operable to store instructions that, when executed by the processor, cause the processor to receive a request to deliver a bolus dosage, retrieve a history of glucose measurement values, extract features from the history of glucose measurement values, assign a value to extracted features and calculate a personalized factor, and based on the personalized factor or factors, modify a calculation for an amount of a medicament to deliver. Additionally or alternatively, the personalized factor may be used to modify parameter settings of a medicament delivery algorithm. The described systems may track a user's personalized factor over a period of time.

公开(公告)号：US20250058042A1

公开(公告)日：2025-02-20

申请号：US18800698

申请日：2024-08-12

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  William WHITELEY ,  Jason O’CONNOR

IPC: A61M5/142

Abstract: The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.

公开(公告)号：US20230377706A1

公开(公告)日：2023-11-23

申请号：US18199641

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Ashutosh ZADE ,  William WHITELEY ,  Jason O’CONNOR

IPC: G16H20/10 ,  A61B5/145 ,  A61B5/00 ,  G16H40/63

CPC classification number: G16H20/10 ,  A61B5/14532 ,  A61B5/4839 ,  G16H40/63

Abstract: The exemplary embodiments may dynamically adjust an Insulin on Board (JOB) profile for a user of a medicament delivery system to customize the IOB profile to the user based on recent glucose level history and insulin deliveries rather than use the conventional static IOB profiles that are based on population averages. The exemplary embodiments may calculate a Duration of Insulin Action (DIA) for a user from the customized insulin decay curves. The exemplary embodiments may generate and send notifications to the user to help reduce the DIA of the user and/or to keep the DIA of the user from rising. The exemplary embodiments may aim to not overly constrain insulin delivery due to the contribution of insulin boluses to JOB.

公开(公告)号：US20240424212A1

公开(公告)日：2024-12-26

申请号：US18824363

申请日：2024-09-04

Applicant: INSULET CORPORATION

Inventor： Rangarajan NARAYANASWAMI ,  Yibin ZHENG ,  Mert SEVIL ,  William WHITELEY ,  Saeed SALAVATI ,  Sam CARL

IPC: A61M5/172

Abstract: The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints.

公开(公告)号：US20240226433A1

公开(公告)日：2024-07-11

申请号：US18390338

申请日：2023-12-20

Applicant: INSULET CORPORATION

Inventor： Rangarajan NARAYANASWAMI ,  Yibin ZHENG ,  Mert SEVIL ,  William WHITELEY ,  Saeed SALAVATI ,  Sam CARL

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2005/1726 ,  A61M2205/505 ,  A61M2230/201

Abstract: The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints.

公开(公告)号：US20250050021A1

公开(公告)日：2025-02-13

申请号：US18797048

申请日：2024-08-07

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  William WHITELEY ,  Jason O’CONNOR

IPC: A61M5/172 ,  G16H20/17

Abstract: Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.

公开(公告)号：US20230402149A1

公开(公告)日：2023-12-14

申请号：US18199638

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  William WHITELEY ,  Saeed SALAVATI ,  Yibin ZHENG ,  Mert SEVIL ,  Jason O’CONNOR

IPC: G16H20/17 ,  A61B5/145 ,  A61B5/00

CPC classification number: G16H20/17 ,  A61B5/7275 ,  A61B5/14532

Abstract: Exemplary embodiments may provide for the switching of glucose prediction models responsive to certain conditions. For example, glucose prediction models may be switched responsive to a detected crashing glucose level condition. Exemplary embodiments also may dynamically customize parameters, such as coefficient values, of the glucose prediction model to a user. The exemplary embodiments may customize the glucose prediction model based on the history of glucose levels of the user and the history of insulin deliveries to the user. The exemplary embodiments may determine a set of parameters that provides an improved fit of the parameters to the history of glucose levels and insulin deliveries of the user. The improved fit parameters may be used to adapt the parameter set to the most recent run.